IC
KYNB

Ikarian Capital’s Kyntra Bio KYNB Stock Holding History

Ikarian Capital’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,000
Closed -$1.08M – 158
2023
Q2 		$1.08M Buy
+16,000
New +$6.62M 0.17% 82
2021
Q3 		– Sell
-10,000
Closed -$6.66M – 231
2021
Q2 		$6.66M Buy
+10,000
New +$5.76M 0.54% 54
2021
Q1 		– Sell
-12,000
Closed -$11.1M – 313
2020
Q4 		$11.1M Buy
12,000
+4,000
+50% +$4.2M 0.49% 46
2020
Q3 		$8.22M Hold
8,000
– – 0.6% 43
2020
Q2 		$8.11M Hold
8,000
– – 0.65% 49
2020
Q1 		$6.95M Buy
+8,000
New +$7.95M 0.52% 50

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's KYNB Position: Q4 2023 in Review

Ikarian Capital sold out of Kyntra Bio (KYNB) in Q4 2023, closing a stake of 111 shares — an estimated $2.39K sold.

Ikarian Capital first reported a position in KYNB in Q2 2023 and held it in 2 quarters. The position peaked at $617K in Q2 2023. 100 funds tracked by Wall St. Rank hold KYNB as of Q4 2023.

  • Ikarian Capital reported no remaining Kyntra Bio position as of Q4 2023 after selling out during the quarter.
  • Ikarian Capital sold 111 Kyntra Bio shares in Q4 2023, an estimated $2.39K.
  • Ikarian Capital first reported a position in Kyntra Bio in Q2 2023 and held it in 2 quarters.
  • Ikarian Capital's Kyntra Bio position peaked at $617K in Q2 2023.
  • 100 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2023.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.